摘要
本专利申请转让给Pneumax LLC(Denver,Colorado,United Sta TES)。以下引文是新闻编辑从新闻编辑提供的背景资料中获得的发明人：“在过去十年中，使用了电子镍钴齿输送系统(ENDS)，如电子烟(ECs)飙升。除了健康成年人的健康问题外，ENDS的使用在青年人群和有潜在肺部疾病的人群中尤其令人担忧(Overbeek)等人，2020年，鲍勒等人，2017年）。自2018年以来，使用ENDS导致的严重肺部腺病毒副作用已经发生。被认为是上升。2019年，美国疾病控制和预防中心(CDC)食品和药物管理局(FDA)开始调查全国爆发的EC或蒸发产品使用相关肺损伤(EVALI)（Reagan-Steiner等人，2020）。伊瓦利导致住院治疗，因严重急性至亚急性肺损伤而死亡。α-生育酚乙酸酯(也已知)作为维生素E醋酸盐[下文称为VEA])，一种发现用作稀释剂的膳食化合物在一些含有大麻的ECs和蒸发产品中，是否与EVALI的爆发有密切联系（Blount等人，2020年，Krishnasamy等人，2020年，Duffy等人，2020年）。到目前为止，（多）的具体原因EVALI不详；然而，对产品和患者样本的分析表明VEA存在ROL E。尽管如此，关于VEA如何导致EVALI的研究还很少，并且仅限于吸入VEAEC气溶胶的实验室鼠模型（Bh at等人，2020年），挑战人类支气管和单核细胞白血病衍生的细胞L系与EC液体（E-Liquid）（Muthumalage等人，2020年），或专注于可溶性VEA的热分解（Wu和O'Shea，2020，Kozlovich等人，2021）。
Abstract
This patent application is assigned to Pneumax LLC (Denver, Colorado, United Sta tes).The following quote was obtained by the news editors from the background informa tion supplied bythe inventors: “Over the past decade the use of electronic nico tine delivery systems (ENDS) such aselectronic cigarettes (ECs), has surged. In addition to health concerns for healthy adults, the use of ENDSamong the youth population and those with underlying lung conditions is particularly of concern (Overbeeket al., 2020, Bowler et al., 2017). Since 2018, serious pulmonary adv erse effects from use of ENDS havebeen noted to be the rise. In 2019, the Unite d States Centers for Disease Control and Prevention (CDC)and the Food and Drug Administration (FDA) begun investigating a national outbreak of EC or vaping pro duct use-associated lung injury (EVALI) (Reagan-Steiner et al., 2020). EVALI led to hospitalizations,as a result of serious acute to subacute lung injury, and fatalities. Alpha-tocopheryl acetate (also knownas vitamin E acetate [hereafter referred to as VEA]), a dietary compound discovered to be used a diluentin some cannabis-containing ECs and vaping products, has b een strongly linked with the EVALI outbreak(Blount et al., 2020, Krishnasamy et al., 2020, Duffy et al., 2020). Thus far, the specific cause(s) ofEVALI is unk nown; however, the analyses of products and patient samples has implicated a rol e for VEA.Despite this, studies on how VEA can lead to EVALI have been sparse a nd limited to inhalation exposure oflaboratory murine models to EC aerosols (Bh at et al., 2020), challenging human bronchial and monocyticleukemia-derived cel l lines with EC liquid (e-liquid) (Muthumalage et al., 2020), or focused on solu bilityand thermal decomposition of VEA (Wu and O’Shea, 2020, Kozlovich et al., 2021).
NETL
NSTL